Fig. 1 · Structure

Documents & Downloads

FMK

Cat. No. A11423 CAS 821794-92-7

RSK inhibitor

FMK is potent, highly specific and irreversible inhibitor of p90 ribosomal protein S6 kinase RSK1 and RSK2; Fmk binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. Fmk induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells.

In Stock

Publications for FMK

1 publication citing this product

  1. Huang-Ming Chang, .et al. , Cell Death Dis, 2021, Apr 17;12(5):409 PMID: 33866326

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FMK targets the C-terminal kinase domain of RSK2. In the original biochemical study, WT RSK2 CTD inhibition had an IC50 of 0.015 ± 0.001 μM, whereas C436V and T493M mutants were less sensitive. Irreversible labeling by the distinct biotin-FMK probe supported the covalent mechanism. In EGF-stimulated COS-7 cells, FMK reduced endogenous RSK2 Ser386 phosphorylation (reported EC50 ~200 nM). [1]

FMK activity depends on assay context and kinase activation state. Independent profiling reported submicromolar IC50 values for Src, Lck, S6K1, Yes and Eph-A2. Already activated RSK1/2 retained substantial activity in that panel. These findings limit interpretation of FMK as an exclusive RSK probe and distinguish prevention of CTD-dependent activation from inhibition of active N-terminal kinase activity. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
COS-7 EC50 200 nM Inhibition of EGF-stimulated RSK2 Ser386 autophosphorylation in serum starved african green monkey COS7 cells by immunoprecipitation and Western blot [PMID: 15919995]
HEK293 EC50 150 nM Inhibition of PMA-stimulated RSK2 phosphorylation in HEK293 cells after 1 hr by Western blotting analysis [PMID: 17259979]
HeLa IC50 39 μM Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay [PMID: 33476933]

FMK Research Summary

This section summarizes 5 in vitro studies of FMK from 4 published references. In vitro models include activated recombinant WT, C436V and T493M RSK2 C-terminal domains; serum-starved COS-7 cells stimulated with EGF.

FMK In Vitro Studies

In human cord blood-derived endothelial progenitor cells, 10 μM FMK pretreatment reduced SDF-1-induced RelA phosphorylation and CXCR4 protein expression without reducing ERK phosphorylation. This was a cellular pathway-probe experiment; the paper’s kidney-protection findings used other interventions. [3]

In primary rat vascular smooth muscle cells, FMK reduced PDGF-BB-induced proliferation-associated readouts, including cell counts, BrdU incorporation and Ki-67. The accompanying Annexin V/PI experiment did not show apoptosis induction at 10 μM FMK under the tested conditions. [4]

RSK2 C-terminal domain inhibition and selectivity-filter controls

Biochemical assay · Activated recombinant WT, C436V and T493M RSK2 C-terminal domains [1]

FMK inhibited WT RSK2 CTD much more strongly than either selectivity-filter mutant. A non-electrophilic scaffold was weaker against WT; labeling by the separate biotin-FMK probe supported a covalent targeting mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wild-type RSK2 C-terminal domain kinase activityIC50 0.015 ± 0.001 μM[1]
C436V RSK2 CTD kinase activityIC50 >10 μM[1]
T493M RSK2 CTD kinase activityIC50 3.4 ± 0.3 μM[1]
WT RSK2 CTD inhibition by non-electrophilic scaffold controlIC50 1.2 ± 0.08 μM[1]
Covalent-labeling control using biotin-FMK, a derivative of FMKQualitative labeling WT RSK2 CTD labeled; C436V, T493M and ERK2 not labeled[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response FMK; exact range not specified in Table 1. Separate labeling control: 1 μM biotin-FMK.
Exposure duration
30-min pretreatment for inhibition; 1 h for biotin-FMK labeling.
Method
Kinase activity assay and mechanistic labeling control.
Reported limits
Main text does not define n or the ± term in Table 1. SI PDF was not retrieved; inhibition reaction duration and vehicle remain unavailable.
Methods and source locations

Compound reported in the paper: FMK; Compound label in the paper: fmk

Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.

Table 1 and caption; biochemical RSK2 Results; Fig. 1B and Fig. 2A/caption

Wild-type RSK2 C-terminal domain kinase activity: 1 nM activated RSK2 CTD, 0.1 mM ATP, 0.1 mM CTD-tide; 30-min inhibitor pretreatment. — Table 1, fmk row, WT column and caption

C436V RSK2 CTD kinase activity: Same Table 1 assay; mutant activities reported similar to WT. — Table 1, fmk row, C436V column

T493M RSK2 CTD kinase activity: Same Table 1 assay. — Table 1, fmk row, T493M column

WT RSK2 CTD inhibition by non-electrophilic scaffold control: Comparator scaffold, not FMK; same Table 1 assay. — Table 1, scaffold row, WT column

Covalent-labeling control using biotin-FMK, a derivative of FMK: 1 μM biotin-FMK for 1 h; denaturing electrophoresis and streptavidin-HRP with His6 protein detection controls. This is not a potency measurement of parent FMK. — Fig. 2A image/caption and preceding Results paragraph

Endogenous RSK2 activation in EGF-stimulated COS-7 cells

Cell-based study · Serum-starved COS-7 cells stimulated with EGF [1]

FMK reduced endogenous RSK2 Ser386 autophosphorylation, while 10 μM FMK did not suppress the measured EGF-induced ERK1/2 phosphorylation signal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EGF-induced endogenous RSK2 Ser386 phosphorylationEC50 ~200 nM[1]
EGF-stimulated ERK1/2 phosphorylationQualitative response No inhibition reported at 10 μM FMK[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.3, 1, 3 and 10 μM FMK in Fig. 3A; 10 μM for ERK control.
Exposure duration
20 h serum deprivation; EGF stimulation for 10 min. FMK pretreatment duration unavailable in retrieved main text.
Method
EGF 1 ng/mL; RSK2 immunoprecipitation and immunoblot; phospho/total ERK immunoblot.
Co-treatment
EGF stimulation; no second inhibitor in the selected comparison.
Reported limits
FMK pretreatment duration/vehicle not stated in retrieved main caption; linked SI was not retrieved. No replicate count given for these blots.
Methods and source locations

Compound reported in the paper: FMK; Compound label in the paper: fmk

Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.

Fig. 3A–B images/captions and endogenous RSK2 Results

EGF-induced endogenous RSK2 Ser386 phosphorylation: Author-reported cellular EC50; not read from a curve. Total RSK2 loading/control blot. — Fig. 3A image/caption and preceding endogenous RSK2 Results paragraph

EGF-stimulated ERK1/2 phosphorylation: Phospho-ERK and total ERK blots; EGF-only and unstimulated controls. — Fig. 3B image/caption and corresponding Results paragraph

Kinase profiling defines off-target and activation-state limits

Biochemical assay · Purified kinase activity panel, including activated RSK1/RSK2 and non-RSK kinases [2]

The panel found submicromolar inhibition of Src, Lck, S6K1, Yes and Eph-A2. Activated RSK1/2 largely retained catalytic activity, consistent with an inhibitor of CTD-dependent activation rather than direct inhibition of active N-terminal kinase activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of Src kinase activityIC50 0.56 μM[2]
Inhibition of Lck kinase activityIC50 0.75 μM[2]
Inhibition of S6K1 kinase activityIC50 0.95 μM[2]
Inhibition of Yes kinase activityIC50 0.51 μM[2]
Inhibition of Eph-A2 kinase activityIC50 0.76 μM[2]
Activity of already activated RSK1 in FMKPercentage activity remaining 92 ± 6%[2]
Activity of already activated RSK2 in FMKPercentage activity remaining 74 ± 2%[2]

Literature-Reported Treatment Conditions

Treatment concentration
3 μM FMK for Table 3 panel; ten inhibitor concentrations for Table 5 IC50 determinations.
Exposure duration
30-min activity assays at 21 °C.
Method
Radiometric kinase assays; ATP varied by enzyme as specified per measurement.
Reported limits
Vehicle and Table 5 replicate/dispersion details not specified in the selected table caption. Table 3 ± terms are retained without assigning an uncertainty type.
Methods and source locations

Compound reported in the paper: FMK; Compound label in the paper: FMK

Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.

Materials and methods: Materials, Protein kinase assays; Tables 3 and 5; RSK inhibitor discussion

Inhibition of Src kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Src row

Inhibition of Lck kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Lck row

Inhibition of S6K1 kinase activity: Ten inhibitor concentrations; 20 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/S6K1 row

Inhibition of Yes kinase activity: Ten inhibitor concentrations; 20 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Yes row

Inhibition of Eph-A2 kinase activity: Ten inhibitor concentrations; 50 μM ATP; 30-min activity assay at 21 °C. — Table 5, FMK/Eph-A2 row

Activity of already activated RSK1 in FMK: 3 μM FMK, 50 μM ATP; inhibitor-omitted control. Duplicate determinations; experiment repeated two or three times with similar results. Caption does not define ± term. — Table 3, RSK1 row, FMK (3 μM) column and caption

Activity of already activated RSK2 in FMK: 3 μM FMK, 50 μM ATP; inhibitor-omitted control. Duplicate determinations; experiment repeated two or three times with similar results. Caption does not define ± term. — Table 3, RSK2 row, FMK (3 μM) column and caption

SDF-1 signaling in human endothelial progenitor cells

Cell-based study · Human umbilical cord blood-derived late endothelial progenitor cells [3]

FMK pretreatment decreased SDF-1-induced RelA phosphorylation and CXCR4 protein expression without reducing ERK phosphorylation in the selected immunoblots.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SDF-1-induced RelA phosphorylationQualitative response Decreased with FMK[3]
SDF-1-induced CXCR4 protein expressionQualitative response Decreased with FMK[3]
SDF-1-induced ERK phosphorylationQualitative response Not reduced by FMK[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM FMK.
Exposure duration
FMK pretreatment 30 min; SDF-1 stimulation 10 min for signaling or 6 h for CXCR4.
Method
SDF-1 100 ng/mL; immunoblots with total-protein and β-actin controls.
Vehicle
DMSO negative control.
Co-treatment
SDF-1 challenge; PD98059 and Helenalin tested separately as pathway comparators.
Reported limits
General methods state western blots were performed at least in triplicate; independent donor n is not specified for Fig. 3B. No catalog number or lot specified.
Methods and source locations

Compound reported in the paper: FMK; Compound label in the paper: FMK

Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.

Fig. 3B image/caption; Results: SDF-1 induces CXCR4 expression via the non-canonical NF-κB signaling pathway in EPCs; Methods: Isolation of EPCs and cell culture; Immunoprecipitation and western blot analysis

SDF-1-induced RelA phosphorylation: Phospho/total RelA immunoblot after 10 min SDF-1. — Fig. 3B upper immunoblots and Results paragraph preceding Fig. 3

SDF-1-induced CXCR4 protein expression: CXCR4 immunoblot after 6 h SDF-1; β-actin loading control. — Fig. 3B lower immunoblots and corresponding Results

SDF-1-induced ERK phosphorylation: Phospho/total ERK control after 10 min SDF-1. — Fig. 3B upper immunoblots and corresponding Results

PDGF-BB-induced proliferation in primary rat vascular smooth muscle cells

Cell-based study · Primary rat VSMCs, passages 4–7, under serum-free experimental conditions [4]

FMK lowered PDGF-BB-induced MTT signal, cell accumulation, BrdU incorporation and Ki-67 readouts. The Annexin V/PI control did not show induction of apoptosis at 10 μM in the tested setting.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PDGF-BB-induced proliferation-associated readoutsQualitative response Reduced by FMK[4]
Apoptosis at 10 μM FMKQualitative response No induction reported[4]

Literature-Reported Treatment Conditions

Treatment concentration
1, 2, 5, 10 μM FMK for MTT; 2 and 5 μM for cell counts/BrdU/Ki-67; 10 μM for apoptosis control.
Exposure duration
1 h pretreatment then 24 h PDGF-BB in Fig. 1. BrdU methods additionally describe a 24 h labeling incubation after the initial 24 h PDGF-BB exposure.
Method
PDGF-BB 2 ng/mL; MTT, cell counting, BrdU, Ki-67 and Annexin V/PI as complementary proliferation/cell-death readouts.
Co-treatment
PDGF-BB stimulus; BI-D1870 is a separate comparator, not a co-treatment.
Reported limits
Vehicle composition not specified. BrdU timing differs in granularity between methods and caption; not collapsed to a single total exposure. Caption describes data representative of three independent experiments.
Methods and source locations

Compound reported in the paper: FMK; Compound label in the paper: FMK

Applies to the reported FMK research material and model; does not validate an Adooq lot or establish clinical efficacy.

Results 2.1; Fig. 1B,D–H images/caption; Methods 4.1–4.2, 4.6–4.7, 4.9–4.11

PDGF-BB-induced proliferation-associated readouts: MTT dose series plus cell counts, BrdU incorporation and Ki-67 staining/blots; unstimulated and PDGF-BB-only controls. — Fig. 1B,D,F–H images/caption; Results 2.1; Methods 4.6–4.7

Apoptosis at 10 μM FMK: Annexin V-FITC/PI flow cytometry; this endpoint does not establish general safety or absence of all cytotoxicity. — Fig. 1E image/caption; Results 2.1; Methods 4.11

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 821794-92-7
Applications RSK inhibitor
Formula C18H19FN4O2
Molecular Weight 342.37
SMILES
CC1=CC=C(C=C1)C2=C(N(C3=C2C(=NC=N3)N)CCCO)C(=O)CF

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FMK Research References

  1. [1] Cohen MS, Zhang C, Shokat KM, et al. Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science (New York, N.Y.) (2005). PMID: 15919995 DOI: 10.1126/science1108367 Source material
  2. [2] Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update The Biochemical journal (2007). PMID: 17850214 DOI: 10.1042/bj20070797 Source material
  3. [3] Chang HM, Peng KY, Chan CK, et al. FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling Cell death & disease (2021). PMID: 33866326 DOI: 10.1038/s41419-021-03693-w Source material
  4. [4] Hwang AR, Lee HJ, Kim S, et al. Inhibition of p90RSK Ameliorates PDGF-BB-Mediated Phenotypic Change of Vascular Smooth Muscle Cell and Subsequent Hyperplasia of Neointima International journal of molecular sciences (2023). PMID: 37175802 DOI: 10.3390/ijms24098094 Source material

Publications

1 publication citing this product

  1. Huang-Ming Chang, .et al. , Cell Death Dis, 2021, Apr 17;12(5):409 PMID: 33866326

Added to your cart

View Cart Checkout
Loading...